Using monoclonal antibodies to stimulate antitumor cellular immunity

References

• Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood83(2), 435–445 (1994).
   PubMed Web of Science ®Google Scholar
• Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol. Immunol.44(16), 3823–3837 (2007).
   PubMed Web of Science ®Google Scholar
• Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am. J. Transplant.6(5 Pt 1), 859–866 (2006).
   PubMed Web of Science ®Google Scholar
• Barok M, Isola J, Palyi-Krekk Z et al. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol. Cancer Ther.6(7), 2065–2072 (2007).
   PubMed Web of Science ®Google Scholar
• Carter P, Presta L, Gorman CM et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl Acad. Sci. USA89(10), 4285–4289 (1992).
   PubMed Web of Science ®Google Scholar
• Hudis CA. Trastuzumab–mechanism of action and use in clinical practice. N. Engl. J. Med.357(1), 39–51 (2007).
   PubMed Web of Science ®Google Scholar
• Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK. Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature416(6878), 279–280 (2002).
   PubMed Web of Science ®Google Scholar
• Alinari L, Lapalombella R, Andritsos L, Baiocchi RA, Lin TS, Byrd JC. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene26(25), 3644–3653 (2007).
   PubMed Web of Science ®Google Scholar
• Hale G, Dyer MJ, Clark MR et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet2(8625), 1394–1399 (1988).
   PubMed Web of Science ®Google Scholar
• Ravandi F, O’Brien S. Alemtuzumab. Expert Rev. Anticancer Ther.5(1), 39–51 (2005).
   PubMed Web of Science ®Google Scholar
• Galizia G, Lieto E, De Vita F et al. Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. Oncogene26(25), 3654–3660 (2007).
   PubMed Web of Science ®Google Scholar
• Kawaguchi Y, Kono K, Mimura K, Sugai H, Akaike H, Fujii H. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int. J. Cancer120(4), 781–787 (2007).
   PubMed Web of Science ®Google Scholar
• Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin. Cancer Res.3(12 Pt 2), 2703–2707 (1997).
   PubMed Web of Science ®Google Scholar
• Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature362(6423), 841–844 (1993).
   PubMed Web of Science ®Google Scholar
• Kramer I, Lipp HP. Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. J. Clin. Pharm Ther.32(1), 1–14 (2007).
   PubMed Web of Science ®Google Scholar
• Presta LG, Chen H, O’Connor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res.57(20), 4593–4599 (1997).
   PubMed Web of Science ®Google Scholar
• Cohenuram M, Saif MW. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs18(1), 7–15 (2007).
   PubMed Web of Science ®Google Scholar
• Jakobovits A, Amado RG, Yang X, Roskos L, Schwab G. From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat. Biotechnol.25(10), 1134–1143 (2007).
   PubMed Web of Science ®Google Scholar
• Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med.6(4), 443–446 (2000).
   PubMed Web of Science ®Google Scholar
• Fan Z, Masui H, Altas I, Mendelsohn J. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res.53(18), 4322–4328 (1993).
   PubMed Web of Science ®Google Scholar
• Desjarlais JR, Lazar GA, Zhukovsky EA, Chu SY. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer’s perspective. Drug Discov. Today12(21–22), 898–910 (2007).
   PubMed Web of Science ®Google Scholar
• Clynes R. Antitumor antibodies in the treatment of cancer: Fc receptors link opsonic antibody with cellular immunity. Hematol. Oncol. Clin. North Am.20(3), 585–612 (2006).
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. Fcγ receptors: old friends and new family members. Immunity24(1), 19–28 (2006).
   PubMed Web of Science ®Google Scholar
• Klos A, Tenner AJ, Johswich KO, Ager RR, Reis ES, Kohl J. The role of the anaphylatoxins in health and disease. Mol. Immunol.46(14), 2753–2766 (2009).
   PubMed Web of Science ®Google Scholar
• Regnault A, Lankar D, Lacabanne V et al. Fcγ receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J. Exp. Med.189(2), 371–380 (1999).
   PubMed Web of Science ®Google Scholar
• Boruchov AM, Heller G, Veri MC, Bonvini E, Ravetch JV, Young JW. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J. Clin. Invest.115(10), 2914–2923 (2005).
   PubMed Web of Science ®Google Scholar
• Schakel K, Mayer E, Federle C, Schmitz M, Riethmuller G, Rieber EP. A novel dendritic cell population in human blood: one-step immunomagnetic isolation by a specific mAb (M-DC8) and in vitro priming of cytotoxic T lymphocytes. Eur. J. Immunol.28(12), 4084–4093 (1998).
   PubMed Web of Science ®Google Scholar
• Abes R, Gelize E, Fridman WH, Teillaud JL. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood116(6), 926–934 (2010).
   PubMed Web of Science ®Google Scholar
• Selenko N, Majdic O, Jager U, Sillaber C, Stockl J, Knapp W. Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies? J. Clin. Immunol.22(3), 124–130 (2002).
   PubMed Web of Science ®Google Scholar
• Taylor C, Hershman D, Shah N et al. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin. Cancer Res.13(17), 5133–5143 (2007).
   PubMed Web of Science ®Google Scholar
• Horlock C, Stott B, Dyson PJ et al. The effects of trastuzumab on the CD4+CD25+FOXP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer. Br. J. Cancer100(7), 1061–1067 (2009).
   PubMed Web of Science ®Google Scholar
• Park S, Jiang Z, Mortenson ED et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell18(2), 160–170.
   Google Scholar
• Gilboa E. DC-based cancer vaccines. J. Clin. Invest.117(5), 1195–1203 (2007).
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Ugurel S, Schuler-Thurner B et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized Phase III trial of the DC study group of the DeCOG. Ann. Oncol.17(4), 563–570 (2006).
   PubMed Web of Science ®Google Scholar
• Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol.24(19), 3089–3094 (2006).
   PubMed Web of Science ®Google Scholar
• Dhodapkar KM, Kaufman JL, Ehlers M et al. Selective blockade of inhibitory Fcγ receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc. Natl Acad. Sci. USA102(8), 2910–2915 (2005).
   PubMed Web of Science ®Google Scholar
• Kalergis AM, Ravetch JV. Inducing tumor immunity through the selective engagement of activating Fcγ receptors on dendritic cells. J. Exp. Med.195(12), 1653–1659 (2002).
   PubMed Web of Science ®Google Scholar
• Akiyama K, Ebihara S, Yada A et al. Targeting apoptotic tumor cells to Fc γ R provides efficient and versatile vaccination against tumors by dendritic cells. J. Immunol.170(4), 1641–1648 (2003).
   PubMed Web of Science ®Google Scholar
• Rafiq K, Bergtold A, Clynes R. Immune complex-mediated antigen presentation induces tumor immunity. J. Clin. Invest.110(1), 71–79 (2002).
   PubMed Web of Science ®Google Scholar
• You Z, Huang X, Hester J, Toh HC, Chen SY. Targeting dendritic cells to enhance DNA vaccine potency. Cancer Res.61(9), 3704–3711 (2001).
   PubMed Web of Science ®Google Scholar
• Qin H, Zhou C, Wang D et al. Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens. Immunol. Lett.99(1), 85–93 (2005).
   PubMed Web of Science ®Google Scholar
• Harbers SO, Crocker A, Catalano G et al. Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance. J. Clin. Invest.117(5), 1361–1369 (2007).
   PubMedGoogle Scholar
• Kim PS, Armstrong TD, Song H et al. Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs. J. Clin. Invest.118(5), 1700–1711 (2008).
   PubMedGoogle Scholar
• Saenger YM, Li Y, Chiou KC et al. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma. Cancer Res.68(23), 9884–9891 (2008).
   Google Scholar
• Weiner LM, Dhodapkar MV, Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet373(9668), 1033–1040 (2009).
   PubMed Web of Science ®Google Scholar
• Pfisterer J, du Bois A, Sehouli J et al. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A Phase I trial of the AGO-OVAR. Ann. Oncol.17(10), 1568–1577 (2006).
   PubMed Web of Science ®Google Scholar
• Reinartz S, Kohler S, Schlebusch H et al. Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (Phase Ib/II). Clin. Cancer Res.10(5), 1580–1587 (2004).
   PubMed Web of Science ®Google Scholar
• Sabbatini P, Dupont J, Aghajanian C et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin. Cancer Res.12(18), 5503–5510 (2006).
   PubMed Web of Science ®Google Scholar
• Wagner U, Kohler S, Reinartz S et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin. Cancer Res.7:1112–1115, 2001. Clin. Cancer Res.7(5), 1154–1162 (2001).
   PubMed Web of Science ®Google Scholar
• Diaz Y, Gonzalez A, Lopez A, Perez R, Vazquez AM, Montero E. Anti-ganglioside anti-idiotypic monoclonal antibody-based cancer vaccine induces apoptosis and antiangiogenic effect in a metastatic lung carcinoma. Cancer Immunol. Immunother.58(7), 1117–1128 (2009).
   PubMed Web of Science ®Google Scholar
• Amin S, Robins RA, Maxwell-Armstrong CA, Scholefield JH, Durrant LG. Vaccine-induced apoptosis: a novel clinical trial end point? Cancer Res.60(12), 3132–3136 (2000).
   PubMed Web of Science ®Google Scholar
• Pritchard-Jones K, Wilton C, Spendlove I et al. Immune responses to the 105AD7 human anti-idiotypic vaccine after intensive chemotherapy for osteosarcoma. 92(8), 1358–1365 (2005).
   Google Scholar
• Ullenhag GJ, Mukherjee A, Watson NF, Al-Attar AH, Scholefield JH, Durrant LG. Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients. Clin. Cancer Res.13(17), 5070–5075 (2007).
   Google Scholar
• Ullenhag GJ, Spendlove I, Watson NF, Kallmeyer C, Pritchard-Jones K, Durrant LG. T-cell responses in osteosarcoma patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55. Clin. Immunol.128(2), 148–154 (2008).
   PubMed Web of Science ®Google Scholar
• Billetta R, Hollingdale MR, Zanetti M. Immunogenicity of an engineered internal image antibody. Proc. Natl Acad. Sci. USA88(11), 4713–4717 (1991).
   PubMed Web of Science ®Google Scholar
• Brumeanu TD, Swiggard WJ, Steinman RM, Bona CA, Zaghouani H. Efficient loading of identical viral peptide onto class II molecules by antigenized immunoglobulin and influenza virus. J. Exp. Med.178(5), 1795–1799 (1993).
   PubMed Web of Science ®Google Scholar
• Li S, Polonis V, Isobe H et al. Chimeric influenza virus induces neutralizing antibodies and cytotoxic T cells against human immunodeficiency virus type 1. J. Virol.67(11), 6659–6666 (1993).
   PubMed Web of Science ®Google Scholar
• Kuzu Y, Kuzu H, Zaghouani H, Bona C. Priming of cytotoxic T lymphocytes at various stages of ontogeny with transfectoma cells expressing a chimeric Ig heavy chain gene bearing an influenza virus nucleoprotein peptide. Int. Immunol.5(10), 1301–1307 (1993).
   PubMed Web of Science ®Google Scholar
• Zaghouani H, Steinman R, Nonacs R, Shah H, Gerhard W, Bona C. Presentation of a viral T cell epitope expressed in the CDR3 region of a self immunoglobulin molecule. Science259(5092), 224–227 (1993).
   PubMed Web of Science ®Google Scholar
• Bot A, Smith D, Phillips B, Bot S, Bona C, Zaghouani H. Immunologic control of tumors by in vivo Fc γ receptor-targeted antigen loading in conjunction with double-stranded RNA-mediated immune modulation. J. Immunol.176(3), 1363–1374 (2006).
   PubMed Web of Science ®Google Scholar
• Metheringham RL, Pudney VA, Gunn B, Towey M, Spendlove I, Durrant LG. Antibodies designed as effective cancer vaccines. MABs1(1), 71–85 (2009).
   PubMed Web of Science ®Google Scholar
• Pudney VA, Metheringham RL, Gunn B, Spendlove I, Ramage JM, Durrant LG. DNA vaccination with T-cell epitopes encoded within Ab molecules induces high-avidity anti-tumor CD8+ T cells. Eur. J. Immunol.40(3), 899–910 (2010).
   PubMed Web of Science ®Google Scholar
• Fuller DH, Loudon P, Schmaljohn C. Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases. Methods40(1), 86–97 (2006).
   PubMed Web of Science ®Google Scholar
• Ahlen G, Soderholm J, Tjelle T et al.In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells. J. Immunol.179(7), 4741–4753 (2007).
   PubMed Web of Science ®Google Scholar
• van Drunen Littel-van den Hurk S, Lawman Z, Wilson D et al. Electroporation enhances immune responses and protection induced by a bovine viral diarrhea virus DNA vaccine in newborn calves with maternal antibodies. Vaccine28(39), 6445–6454 (2010).
   PubMedGoogle Scholar
• Fredriksen AB, Sandlie I, Bogen B. DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells. Mol. Ther.13(4), 776–785 (2006).
   PubMedGoogle Scholar
• Tunheim G, Thompson KM, Fredriksen AB, Espevik T, Schjetne KW, Bogen B. Human receptors of innate immunity (CD14, TLR2) are promising targets for novel recombinant immunoglobulin-based vaccine candidates. Vaccine25(24), 4723–4734 (2007).
   Google Scholar
• Hawiger D, Inaba K, Dorsett Y et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med.194(6), 769–779 (2001).
   PubMed Web of Science ®Google Scholar
• Mahnke K, Qian Y, Fondel S, Brueck J, Becker C, Enk AH. Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice. Cancer Res.65(15), 7007–7012 (2005).
   PubMed Web of Science ®Google Scholar
• Charalambous A, Oks M, Nchinda G, Yamazaki S, Steinman RM. Dendritic cell targeting of survivin protein in a xenogeneic form elicits strong CD4+ T cell immunity to mouse survivin. J. Immunol.177(12), 8410–8421 (2006).
   PubMed Web of Science ®Google Scholar
• Idoyaga J, Cheong C, Suda K et al. Cutting edge: langerin/CD207 receptor on dendritic cells mediates efficient antigen presentation on MHC I and II products in vivo. J. Immunol.180(6), 3647–3650 (2008).
   Google Scholar
• Demangel C, Zhou J, Choo AB, Shoebridge G, Halliday GM, Britton WJ. Single chain antibody fragments for the selective targeting of antigens to dendritic cells. Mol. Immunol.42(8), 979–985 (2005).
   PubMedGoogle Scholar
• Nchinda G, Kuroiwa J, Oks M et al. The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells. J. Clin. Invest.118(4), 1427–1436 (2008).
   PubMed Web of Science ®Google Scholar
• Grossmann C, Tenbusch M, Nchinda G et al. Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic Toll-like receptor ligands. BMC Immunol.10, 43 (2009).
   PubMed Web of Science ®Google Scholar
• Ramakrishna V, Treml JF, Vitale L et al. Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules. J. Immunol.172(5), 2845–2852 (2004).
   PubMed Web of Science ®Google Scholar
• He LZ, Crocker A, Lee J et al. Antigenic targeting of the human mannose receptor induces tumor immunity. J. Immunol.178(10), 6259–6267 (2007).
   PubMed Web of Science ®Google Scholar
• Luhder F, Huang Y, Dennehy KM et al. Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. J. Exp. Med.197(8), 955–966 (2003).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Palmero M, Hara T, Thumbs A, Hunig T. Triggering of T cell proliferation through CD28 induces GATA-3 and promotes T helper type 2 differentiation in vitro and in vivo. Eur. J. Immunol.29(12), 3914–3924 (1999).
   PubMed Web of Science ®Google Scholar
• Suntharalingam G, Perry MR, Ward S et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med.355(10), 1018–1028 (2006).
   PubMed Web of Science ®Google Scholar
• Alegre ML, Noel PJ, Eisfelder BJ et al. Regulation of surface and intracellular expression of CTLA4 on mouse T cells. J. Immunol.157(11), 4762–4770 (1996).
   PubMed Web of Science ®Google Scholar
• Linsley PS, Bradshaw J, Greene J, Peach R, Bennett KL, Mittler RS. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity4(6), 535–543 (1996).
   PubMed Web of Science ®Google Scholar
• van der Merwe PA, Bodian DL, Daenke S, Linsley P, Davis SJ. CD80 (B7–1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J. Exp. Med.185(3), 393–403 (1997).
   PubMed Web of Science ®Google Scholar
• Chambers CA, Sullivan TJ, Truong T, Allison JP. Secondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8+ T cells. Eur. J. Immunol.28(10), 3137–3143 (1998).
   PubMed Web of Science ®Google Scholar
• Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity3(5), 541–547 (1995).
   PubMed Web of Science ®Google Scholar
• Waterhouse P, Penninger JM, Timms E et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science270(5238), 985–988 (1995).
   PubMed Web of Science ®Google Scholar
• Morse MA. Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb. Curr. Opin. Mol. Ther.7(6), 588–597 (2005).
   PubMed Web of Science ®Google Scholar
• Read S, Greenwald R, Izcue A et al. Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo. J. Immunol.177(7), 4376–4383 (2006).
   PubMed Web of Science ®Google Scholar
• Sansom DM, Walker LS. The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology. Immunol. Rev.212, 131–148 (2006).
   PubMed Web of Science ®Google Scholar
• Takahashi T, Tagami T, Yamazaki S et al. Immunologic self-tolerance maintained by CD25+ CD4+ regulatory T Cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med.192(2), 303–309 (2000).
   PubMed Web of Science ®Google Scholar
• Grohmann U, Orabona C, Fallarino F et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol.3(11), 1097–1101 (2002).
   PubMed Web of Science ®Google Scholar
• Ying H, Yang L, Qiao G et al. Cutting edge: CTLA-4–B7 interaction suppresses Th17 cell differentiation. J. Immunol.185(3), 1375–1378 (2010).
   PubMed Web of Science ®Google Scholar
• Kwon ED, Hurwitz AA, Foster BA et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc. Natl Acad. Sci. USA94(15), 8099–8103 (1997).
   PubMed Web of Science ®Google Scholar
• Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science271(5256), 1734–1736 (1996).
   PubMed Web of Science ®Google Scholar
• Yang YF, Zou JP, Mu J et al. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res.57(18), 4036–4041 (1997).
   PubMed Web of Science ®Google Scholar
• Sutmuller RP, van Duivenvoorde LM, van Elsas A et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med.194(6), 823–832 (2001).
   PubMed Web of Science ®Google Scholar
• Hurwitz AA, Foster BA, Kwon ED et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res.60(9), 2444–2448 (2000).
   PubMed Web of Science ®Google Scholar
• Hurwitz AA, Yu TF, Leach DR, Allison JP. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl Acad. Sci. USA95(17), 10067–10071 (1998).
   PubMed Web of Science ®Google Scholar
• van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med.190(3), 355–366 (1999).
   PubMed Web of Science ®Google Scholar
• Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J. Clin. Invest.116(7), 1935–1945 (2006).
   PubMed Web of Science ®Google Scholar
• Quezada SA, Simpson TR, Peggs KS et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J. Exp. Med.207(3), 637–650 (2010).
   PubMed Web of Science ®Google Scholar
• Camacho LH, Antonia S, Sosman J et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J. Clin. Oncol.27(7), 1075–1081 (2009).
   PubMed Web of Science ®Google Scholar
• Robert C, Ghiringhelli F. What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? Oncologist14(8), 848–861 (2009).
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med.363(8), 711–723 (2010).
   PubMed Web of Science ®Google Scholar
• Maker AV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J. Immunol.175(11), 7746–7754 (2005).
   PubMed Web of Science ®Google Scholar
• Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol.26, 677–704 (2008).
   PubMed Web of Science ®Google Scholar
• Nishimura H, Okazaki T, Tanaka Y et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science291(5502), 319–322 (2001).
   PubMed Web of Science ®Google Scholar
• Nishimura T, Iwakabe K, Sekimoto M et al. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J. Exp. Med.190(5), 617–627 (1999).
   PubMed Web of Science ®Google Scholar
• Hamanishi J, Mandai M, Iwasaki M et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl Acad. Sci. USA104(9), 3360–3365 (2007).
   PubMed Web of Science ®Google Scholar
• Thompson RH, Kuntz SM, Leibovich BC et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res.66(7), 3381–3385 (2006).
   PubMed Web of Science ®Google Scholar
• Blank C, Brown I, Marks R, Nishimura H, Honjo T, Gajewski TF. Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells. J. Immunol.171(9), 4574–4581 (2003).
   PubMedGoogle Scholar
• Keir ME, Freeman GJ, Sharpe AH. PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues. J. Immunol.179(8), 5064–5070 (2007).
   PubMed Web of Science ®Google Scholar
• Ansari MJ, Salama AD, Chitnis T et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J. Exp. Med.198(1), 63–69 (2003).
   PubMed Web of Science ®Google Scholar
• Keir ME, Liang SC, Guleria I et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J. Exp. Med.203(4), 883–895 (2006).
   PubMed Web of Science ®Google Scholar
• Probst HC, McCoy K, Okazaki T, Honjo T, van den Broek M. Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat. Immunol.6(3), 280–286 (2005).
   PubMed Web of Science ®Google Scholar
• Francisco LM, Salinas VH, Brown KE et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med.206(13), 3015–3029 (2009).
   PubMed Web of Science ®Google Scholar
• Latchman Y, Wood CR, Chernova T et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol.2(3), 261–268 (2001).
   PubMed Web of Science ®Google Scholar
• Parry RV, Chemnitz JM, Frauwirth KA et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell Biol.25(21), 9543–9553 (2005).
   PubMed Web of Science ®Google Scholar
• Barber DL, Wherry EJ, Masopust D et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature439(7077), 682–687 (2006).
   PubMed Web of Science ®Google Scholar
• Fourcade J, Kudela P, Sun Z et al. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J. Immunol.182(9), 5240–5249 (2009).
   PubMed Web of Science ®Google Scholar
• Wong RM, Scotland RR, Lau RL et al. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int. Immunol.19(10), 1223–1234 (2007).
   PubMed Web of Science ®Google Scholar
• Blank C, Brown I, Peterson AC et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res.64(3), 1140–1145 (2004).
   PubMed Web of Science ®Google Scholar
• Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA99(19), 12293–12297 (2002).
   PubMed Web of Science ®Google Scholar
• Strome SE, Dong H, Tamura H et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res.63(19), 6501–6505 (2003).
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol.28(19), 3167–3175 (2010).
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Toplian SL, Powderly J et al. Phase II experience with MDX-1106 (ONO-4538), an anti-PD-1/PD-L1 monoclonal antibody, in patients with selected refractory or relapsed malignancies. J. Clin. Oncol.27 (2008) (Abstract 3015).
   Google Scholar
• Berger R, Rotem-Yehudar R, Slama G et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res.14(10), 3044–3051 (2008).
   PubMed Web of Science ®Google Scholar
• Schuurhuis DH, Laban S, Toes RE et al. Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli. J. Exp. Med.192(1), 145–150 (2000).
   PubMed Web of Science ®Google Scholar
• Diehl L, den Boer AT, Schoenberger SP et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat. Med.5(7), 774–779 (1999).
   PubMed Web of Science ®Google Scholar
• van Mierlo GJ, Boonman ZF, Dumortier HM et al. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication. J. Immunol.173(11), 6753–6759 (2004).
   PubMedGoogle Scholar
• Vonderheide RH, Flaherty KT, Khalil M et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J. Clin. Oncol.25(7), 876–883 (2007).
   PubMed Web of Science ®Google Scholar
• Advani R, Forero-Torres A, Furman RR et al. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin’s lymphoma. J. Clin. Oncol.27(26), 4371–4377 (2009).
   PubMed Web of Science ®Google Scholar
• Weinberg AD, Evans DE, Thalhofer C, Shi T, Prell RA. The generation of T cell memory: a review describing the molecular and cellular events following OX40 (CD134) engagement. J. Leukoc. Biol.75(6), 962–972 (2004).
   PubMed Web of Science ®Google Scholar
• Evans DE, Prell RA, Thalhofer CJ, Hurwitz AA, Weinberg AD. Engagement of OX40 enhances antigen-specific CD4(+) T cell mobilization/memory development and humoral immunity: comparison of αOX-40 with αCTLA-4. J. Immunol.167(12), 6804–6811 (2001).
   PubMed Web of Science ®Google Scholar
• Kjaergaard J, Tanaka J, Kim JA, Rothchild K, Weinberg A, Shu S. Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res.60(19), 5514–5521 (2000).
   PubMed Web of Science ®Google Scholar
• Redmond WL, Gough MJ, Charbonneau B, Ratliff TL, Weinberg AD. Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist. J. Immunol.179(11), 7244–7253 (2007).
   PubMed Web of Science ®Google Scholar
• Weinberg AD, Rivera MM, Prell R et al. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J. Immunol.164(4), 2160–2169 (2000).
   PubMed Web of Science ®Google Scholar
• Kovacsovics-Bankowski M WE, Floyd k et al. Increased CD4 and CD8 memory T cell proliferation following anti-OX40 administration to cancer patients: immunologic assessment of a Phase I clinical trial. Curr. Opin. Oncol.23(2), 163–169 (2009).
   Google Scholar
• Alderson MR, Smith CA, Tough TW et al. Molecular and biological characterization of human 4-1BB and its ligand. Eur. J. Immunol.24(9), 2219–2227 (1994).
   PubMed Web of Science ®Google Scholar
• Gramaglia I, Cooper D, Miner KT, Kwon BS, Croft M. Co-stimulation of antigen-specific CD4 T cells by 4-1BB ligand. Eur. J. Immunol.30(2), 392–402 (2000).
   Google Scholar
• Shuford WW, Klussman K, Tritchler DD et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J. Exp. Med.186(1), 47–55 (1997).
   PubMed Web of Science ®Google Scholar
• Miller RE, Jones J, Le T et al. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. J. Immunol.169(4), 1792–1800 (2002).
   PubMed Web of Science ®Google Scholar
• Sznol M, Hodi FS, Margolin K et al. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer. J. Clin. Oncol.26(Suppl.), (2008) (Abstract 3007).
   Google Scholar